Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Processa Pharmaceuticals, Inc.
Bear Case (25th pct.)
145.7% vs price
Base Case (Median)
177.6% vs price
Bull Case (75th pct.)
209.4% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $4.23 | 113.8% | High (40%) |
| Graham Number | $6.75 | 241.5% | Medium (40%) |
Based on 2 out of 7 methods, PCSA appears undervalued at the current price of $1.98. The base case fair value of $5.49 implies 177.6% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.